Stock 4547 KISSEI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kissei Pharmaceutical Co., Ltd.

Equities

4547

JP3240600001

Market Closed - Japan Exchange
Other stock markets
 07:00:00 13/05/2024 BST 		5-day change 1st Jan Change
3,130 JPY -1.73% Intraday chart for Kissei Pharmaceutical Co., Ltd. -14.36% +1.29%
05-08 Japanese Shares Swing to Red Amid Profit-Taking, US Rate Cut Uncertainty MT
05-08 Kissei Pharmaceutical's Attributable Profit Jumps 6% in Fiscal 2023; Shares Tumble 11% MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Japanese Shares Swing to Red Amid Profit-Taking, US Rate Cut Uncertainty
MT
Kissei Pharmaceutical's Attributable Profit Jumps 6% in Fiscal 2023; Shares Tumble 11%
MT
Final dividend
FA
Kissei Pharmaceutical Completes 6 Billion Yen Buyback Program
MT
Kissei Pharmaceutical : Notice Concerning Status of Acquisition and Completion of the Company's Own Shares
PU
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.
CI
Kissei Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 8, 2023, has closed with 1,909,900 shares, representing 4.18% for ¥5,999.99 million.
CI
Kissei Pharmaceutical : Notice Concerning Status of Acquisition of the Company's Own Shares
PU
Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024
CI
Kissei Pharmaceutical Repurchases 251 Million Yen Worth of Shares in December 2023
MT
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.
CI
Kissei and Maruishi Debut Injection for Dialysis-Related Itching
MT
Kissei Pharmaceutical : KORSUVA® IV Injection Syringe for Dialysis 17.5μg, 25.0μg and 35.0μg to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis
PU
Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis
CI
Kissei Pharmaceutical : Notice Concerning Status of Acquisition of the Company's Own Shares
PU
Kissei Pharmaceutical : Introduces Natural Language Processing System
PU
Japanese Shares Close Lower on Tuesday After Key Economic Data
MT
Kissei Pharmaceutical's Fiscal H1 Attributable Profit Surges as Net Sales Gains
MT
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
CI
Kissei Pharmaceutical Co., Ltd. Announces Second Quarter-End Dividend for the Year Ending March 31, 2024, Payable on December 4, 2023 and Provided Dividend Guidance for the Year Ending March 31, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4547 Stock
  4. News Kissei Pharmaceutical Co., Ltd.